

Marcello Tucci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4778337/publications.pdf>

Version: 2024-02-01

51
papers

1,512
citations

331538

21
h-index

315616

38
g-index

51
all docs

51
docs citations

51
times ranked

2770
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide. <i>Minerva Urology and Nephrology</i> , 2022, 73, .	1.3	4
2	Adverse event assessment in prostate cancer patients receiving androgen deprivation therapy: are we doing enough?. <i>Minerva Urology and Nephrology</i> , 2022, 73, 870-872.	1.3	3
3	Prognostic factors in metastatic castration resistant prostate cancer patients treated with Radium-223: a retrospective study. <i>Minerva Urology and Nephrology</i> , 2022, , .	1.3	2
4	Role of radium-223 discontinuation due to adverse events in castration-resistant prostate cancer patients. A retrospective monocentric analysis. <i>Tumori</i> , 2022, , 030089162210771.	0.6	1
5	The Role of Fast and Deep PSA Response in Castration-sensitive Prostate Cancer. <i>Anticancer Research</i> , 2022, 42, 165-172.	0.5	4
6	New emerging targets in advanced urothelial carcinoma: Is it the primetime for personalized medicine?. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 174, 103682.	2.0	5
7	Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103185.	2.0	41
8	Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetate. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 812-825.	2.0	5
9	Antiangiogenic Therapy in Clear Cell Renal Carcinoma (CCRC): Pharmacological Basis and Clinical Results. <i>Cancers</i> , 2021, 13, 5896.	1.7	15
10	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 105-120.	5.1	61
11	Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. <i>JAMA Network Open</i> , 2020, 3, e2021692.	2.8	70
12	Bipolar androgen therapy in prostate cancer: Current evidences and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 152, 102994.	2.0	13
13	Overcoming the mechanisms of primary and acquired resistance to new generation hormonal therapies in advanced prostate cancer: focus on androgen receptor independent pathways. , 2020, 3, 726-741.		6
14	Prognostic role of early PSA drop in castration resistant prostate cancer patients treated with abiraterone acetate or enzalutamide. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 737-745.	3.9	6
15	Quality-of-Life Assessment and Reporting in Prostate Cancer: Systematic Review of Phase 3 Trials Testing Anticancer Drugs Published Between 2012 and 2018. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 332-347.e2.	0.9	9
16	Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian study. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987772.	1.4	16
17	Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 291-298.	0.9	30
18	Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era. <i>Cancer Treatment Reviews</i> , 2019, 74, 35-42.	3.4	30

#	ARTICLE	IF	CITATIONS
19	Sequencing chemotherapy and immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (UC): Meet-Uro1 study.. Journal of Clinical Oncology, 2019, 37, e16013-e16013.	0.8	1
20	Quality-of-life (QoL) assessment and reporting in prostate cancer: A systematic review of phase III trials published between 2012 and 2016.. Journal of Clinical Oncology, 2019, 37, 219-219.	0.8	3
21	Prostate cancer management at an Italian tertiary referral center: does multidisciplinary team meeting influence diagnostic and therapeutic decision-making process? A snapshot of the everyday clinical practice. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 576-582.	3.9	16
22	The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer, 2018, 16, e223-e231.	0.9	27
23	Antiandrogen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer. Endocrine-Related Cancer, 2018, 25, R1-R9.	1.6	13
24	Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions. OncoTargets and Therapy, 2018, Volume 11, 7353-7368.	1.0	58
25	Hormonal treatment and quality of life of prostate cancer patients: new evidence. Minerva Urology and Nephrology, 2018, 70, 144-151.	1.3	25
26	Role of radiotherapy in improving activity of immune-modulating drugs in advanced renal cancer: Biological rationale and clinical evidences. Cancer Treatment Reviews, 2018, 69, 215-223.	3.4	19
27	FOLFOX activity in a rare case of metastatic colonic adenocarcinoma of the tongue: a case report. BMC Cancer, 2018, 18, 470.	1.1	0
28	Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. Clinical Genitourinary Cancer, 2018, 16, e945-e951.	0.9	30
29	Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2018, 129, 124-132.	2.0	18
30	De novo metastatic castration sensitive prostate cancer: State of art and future perspectives. Cancer Treatment Reviews, 2018, 70, 67-74.	3.4	41
31	Metastatic Renal Medullary Carcinoma Treated With Immune Checkpoint Inhibitor: Case Report and Literature Review. Clinical Genitourinary Cancer, 2018, 16, e1087-e1090.	0.9	4
32	Chemotherapy-Induced Neutropenia and Outcome in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With First-Line Docetaxel. Clinical Genitourinary Cancer, 2018, 16, 318-324.	0.9	4
33	Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel. Acta Oncologica, 2017, 56, 555-562.	0.8	24
34	Molecular biomarkers to predict response to neoadjuvant chemotherapy for bladder cancer. Cancer Treatment Reviews, 2017, 54, 1-9.	3.4	44
35	Immediate or Delayed Nephrectomy in Patients With Metastatic Renal Cancer Who Are Receiving Targeted Agents: Is the Analysis at Risk for Guarantee-Time Bias?. Journal of Clinical Oncology, 2017, 35, 1264-1264.	0.8	1
36	Zoledronic Acid Dosing Interval for Metastatic Cancer. JAMA - Journal of the American Medical Association, 2017, 317, 1477.	3.8	0

#	ARTICLE	IF	CITATIONS
37	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2017, 390, 2266-2277.	6.3	153
38	Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives. <i>BioMed Research International</i> , 2017, 2017, 1-13.	0.9	10
39	An exploratory analysis of the association between levels of hormones implied in steroid biosynthesis and activity of abiraterone in patients with metastatic castration-resistant prostate cancer. <i>Minerva Urology and Nephrology</i> , 2017, 69, 349-358.	1.3	3
40	Androgen deprivation modulates gene expression profile along prostate cancer progression. <i>Human Pathology</i> , 2016, 56, 81-88.	1.1	20
41	Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. <i>Future Oncology</i> , 2016, 12, 493-502.	1.1	8
42	Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer. <i>Cancer Treatment Reviews</i> , 2016, 44, 61-73.	3.4	56
43	Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2016, 69, 563-573.	0.9	101
44	Retrospective study testing next generation sequencing of selected cancer-associated genes in resected prostate cancer. <i>Oncotarget</i> , 2016, 7, 14394-14404.	0.8	23
45	Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. <i>European Urology</i> , 2015, 68, 147-153.	0.9	73
46	Metastatic castration-resistant prostate cancer: time for innovation. <i>Future Oncology</i> , 2015, 11, 91-106.	1.1	32
47	Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 265.e15-265.e21.	0.8	6
48	Papillary renal cell carcinoma: A review of the current therapeutic landscape. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 100-112.	2.0	104
49	Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer. <i>Cancer Treatment Reviews</i> , 2015, 41, 884-892.	3.4	141
50	Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment. <i>Oncotarget</i> , 2015, 6, 12520-12528.	0.8	47
51	Chromogranin A Expression in Patients With Hormone Naïve Prostate Cancer Predicts the Development of Hormone Refractory Disease. <i>Journal of Urology</i> , 2007, 178, 838-843.	0.2	86